rs104894011 — GCK Glu265Lys (MODY2)

GCK Glu265Lys — The Pancreatic Glucose Sensor, Set Too High

Glucokinase (GCK) is the enzyme that tells your pancreatic beta cells how much glucose is in the bloodstream. Think of it as a thermostat: it sets the glucose threshold at which insulin secretion begins. Normally, beta cells start releasing insulin when blood glucose rises above about 5.0 mmol/L (90 mg/dL). When glucokinase carries a pathogenic variant like Glu265Lys, that thermostat is set approximately 1–3 mmol/L too high — beta cells remain "unaware" of the glucose until it reaches a higher level than normal, producing mild, lifelong fasting hyperglycemia.

This is MODY2 (Maturity-Onset Diabetes of the Young, type 2), the most common form of monogenic diabetes¹¹ monogenic diabetes
Monogenic diabetes arises from a single-gene defect, as opposed to type 1 or type 2 diabetes which involve many genes and environmental factors. MODY accounts for 1–5% of all diabetes diagnoses but is frequently misdiagnosed as type 1 or type 2.. The Glu265Lys variant substitutes a negatively charged glutamic acid at position 265 of the glucokinase protein with a positively charged lysine residue, destabilizing the protein structure and reducing its functional activity.

The Mechanism

Glucokinase (hexokinase IV) phosphorylates glucose to glucose-6-phosphate, the first step in glycolysis. In beta cells, this reaction couples extracellular glucose concentration directly to insulin secretion. Unlike other hexokinases, glucokinase has a sigmoidal kinetic response to glucose and is not inhibited by its product — properties that make it exquisitely suited as a glucose sensor.

The Glu265Lys substitution²² Glu265Lys substitution
The glutamic acid at codon 265 is located in a structural region of glucokinase (exon 7). Biochemical studies show the mutation primarily destabilizes the protein's tertiary structure — it reduces thermal stability and total functional protein — rather than directly abolishing the active site. shifts the glucose-sensing threshold upward. Beta cells respond to glucose, but they don't begin secreting insulin until blood glucose climbs 1–3 mmol/L higher than normal. This produces fasting glucose values consistently in the range of 5.5–8.0 mmol/L (99–144 mg/dL), with HbA1c typically between 5.6–7.6%.

Crucially, the defect is in the sensor, not in overall beta-cell capacity or insulin action. Insulin secretion is normal once the higher threshold is crossed, and insulin sensitivity is preserved. This is why GCK-MODY behaves so differently from type 1 or type 2 diabetes: there is no progressive beta-cell failure, no insulin resistance, and the hyperglycemia is stable over decades.

The Evidence

Galán et al. (2006)³³ Galán et al. (2006)
Effects of novel MODY-associated mutations on glucokinase activity and protein stability. Biochemical Journal, 2006. directly characterized the Glu265Lys mutation, finding that it "strongly affects protein stability, suggesting a possible structural defect" rather than a kinetic impairment, distinguishing it mechanistically from mutations that abolish enzymatic catalysis.

Estalella et al. (2008)⁴⁴ Estalella et al. (2008)
Biochemical characterization of novel glucokinase mutations isolated from Spanish MODY2 patients. J Human Genetics, 2008. confirmed E265K produces reduced enzymatic activity alongside five other Spanish MODY2 mutations.

Large registry studies establish the clinical picture. A Spanish cohort Estalella et al. (2007)⁵⁵ Estalella et al. (2007)
Mutations in GCK and HNF-1alpha explain the majority of MODY cases in Spain. Clinical Endocrinology, 2007. of 95 families found GCK mutations explained 80% of MODY, with affected individuals managed predominantly by diet alone — in sharp contrast to HNF1A-MODY, which requires sulfonylureas or insulin in most cases.

The Brazilian MODY Registry (2017)⁶⁶ Brazilian MODY Registry (2017)
Giuffrida et al., Diabetes Research and Clinical Practice, 2017 — 311 patients across multiple subtypes. found only 5% of GCK-MODY patients required sulfonylureas and only 5% required insulin — versus 83% and 17% respectively for HNF1A-MODY. Discontinuing pharmacologic therapy in GCK-MODY does not alter HbA1c, confirming the hyperglycemia is a fixed set-point, not progressive dysregulation.

The NIH GeneReviews entry for GCK-MODY⁷⁷ NIH GeneReviews entry for GCK-MODY
Chakera et al., updated regularly. GeneReviews — Glucokinase MODY. NCBI Bookshelf NBK500456. summarizes the diagnostic criteria: fasting glucose 5.5–8.0 mmol/L, HbA1c 5.6–7.3% (age ≤40) or 5.9–7.6% (age >40), present from birth, and not progressive.

Practical Actions

The most important clinical insight for GCK-MODY carriers is that their elevated fasting glucose is a stable set-point, not a disease requiring treatment. Sulfonylureas stimulate insulin secretion below the elevated threshold, producing hypoglycemia without benefit. Insulin provides no sustained glycemic improvement because the beta cells will simply re-establish the same raised threshold. Multiple studies confirm that stopping pharmacologic treatment in previously misdiagnosed GCK-MODY patients does not change HbA1c.

The correct response is accurate diagnosis, family cascade testing (50% of children will inherit the variant), and — in pregnant carriers — specific obstetric management based on fetal genotype.

Pregnancy deserves special attention. If the fetus inherits the GCK variant, its own beta cells will also have the raised threshold, meaning normal fetal insulin production occurs and birth weight is unaffected. If the fetus does NOT inherit the variant, it has normal glucokinase — normal fetal beta cells will produce extra insulin in response to the mildly elevated maternal glucose, promoting excessive fetal growth (macrosomia). In this scenario, maternal insulin therapy during pregnancy can normalize fetal growth; fetal abdominal circumference on ultrasound is used to infer the fetal genotype and guide treatment decisions.

Interactions

GCK-MODY does not interact with the common polygenic type 2 diabetes risk variants in a clinically meaningful way — the mechanism is entirely different (sensor threshold vs progressive beta-cell failure). Carriers of GCK Glu265Lys should inform family members, as the autosomal dominant inheritance pattern means each first-degree relative has a 50% chance of carrying the same variant.

Other GCK coding variants (hundreds have been described) cause the same MODY2 phenotype through distinct mechanisms. Related pathogenic GCK variants tracked in databases include other exon 7 missense mutations. The GCK activation mutations causing congenital hyperinsulinism (the opposite phenotype — hypoglycemia) are entirely distinct.